首页> The Lancet. Oncology> Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.

导出 OA

翻译打印收藏纠错

第一作者： Vicky,Makker

第一单位： Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: makkerV@mskcc.org.

作者： Vicky,Makker ^[1] ; Drew,Rasco ^[2] ; Nicholas J,Vogelzang ^[3] ; Marcia S,Brose ^[4] ; Allen L,Cohn ^[5] ; James,Mier ^[6] ; Christopher,Di Simone ^[7] ; David M,Hyman ^[8] ; Daniel E,Stepan ^[9] ; Corina E,Dutcus ^[9] ; Emmett V,Schmidt ^[10] ; Matthew,Guo ^[9] ; Pallavi,Sachdev ^[9] ; Robert,Shumaker ^[9] ; Carol,Aghajanian ^[8] ; Matthew,Taylor ^[11]

作者单位： Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: makkerV@mskcc.org. ^[1] START, San Antonio, TX, USA. ^[2] Comprehensive Cancer Centers of Nevada and US Oncology Research, Las Vegas, NV, USA. ^[3] Perelman Center for Advanced Medicine, Philadelphia, PA, USA. ^[4] Rocky Mountain Cancer Center and US Oncology Research, Denver, CO, USA. ^[5] Beth Israel Deaconess Medical Center, Boston, MA, USA. ^[6] Arizona Oncology Associates and US Oncology Research, Tucson, AZ, USA. ^[7] Memorial Sloan Kettering Cancer Center, New York, NY, USA. ^[8] Eisai, Woodcliff Lake, NJ, USA. ^[9] Merck, Kenilworth, NJ, USA. ^[10] Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA. ^[11]